Immune response to develop a vaccine against leishmaniasis

Autores
Germano, Maria Jose
Año de publicación
2020
Idioma
inglés
Tipo de recurso
documento de conferencia
Estado
versión publicada
Descripción
Leishmaniasis is an infectious disease caused by flagellated parasites belonging to Leishmania genus and transmitted by phlebotominae sandflies. Leishmaniasis is distributed in 98 countries of the world; in Argentina, the endemic areas are the Northwest and Northeast regions of the country.Leishmania parasites present two different stages: the intracellular amastigote localized in the mammalian polymorphonuclear cells and the extracellular promastigote, presents in the sanfly vector. This disease manifests different clinical forms: cutaneous, mucocutaneous or visceral leishmaniasis, mainly depending on the species of Leishmania involved.There is currently no vaccine against human leishmaniasis. In order to develop that, it is important to considerate the immunology of susceptibility and resistance to leishmaniasis, which depends on the genetic background of host and the specie, and even the specie of Leishmania involved. In consequence, it is possible that a vaccine is effective against one Leishmania specie but not against others.Our research group has been developing first generation vaccine, using Total L. amazonensis Antigens (TLA) which combined with Poly(I:C) and/or Montanide ISA 763 produce a Th1 like immune response and protect against L. amazonensis infection. Using serums of vaccinated mice, immunoproteomic assay was made in order to identify and select the immunodominant antigens, and therefore develop third generation vaccines.
Fil: Germano, Maria Jose. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina
XXXVI Scientific Meeting of the Cuyo Biology Society
Mendoza
Argentina
Sociedad de Biología de Cuyo
Materia
Leishmania
Vaccine
Immunology
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/204449
Acceder
id CONICETDig_105a52ccb8fc24cfc1c5bf7c1301b911
oai_identifier_str oai:ri.conicet.gov.ar:11336/204449
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Immune response to develop a vaccine against leishmaniasisGermano, Maria JoseLeishmaniaVaccineImmunologyhttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1Leishmaniasis is an infectious disease caused by flagellated parasites belonging to Leishmania genus and transmitted by phlebotominae sandflies. Leishmaniasis is distributed in 98 countries of the world; in Argentina, the endemic areas are the Northwest and Northeast regions of the country.Leishmania parasites present two different stages: the intracellular amastigote localized in the mammalian polymorphonuclear cells and the extracellular promastigote, presents in the sanfly vector. This disease manifests different clinical forms: cutaneous, mucocutaneous or visceral leishmaniasis, mainly depending on the species of Leishmania involved.There is currently no vaccine against human leishmaniasis. In order to develop that, it is important to considerate the immunology of susceptibility and resistance to leishmaniasis, which depends on the genetic background of host and the specie, and even the specie of Leishmania involved. In consequence, it is possible that a vaccine is effective against one Leishmania specie but not against others.Our research group has been developing first generation vaccine, using Total L. amazonensis Antigens (TLA) which combined with Poly(I:C) and/or Montanide ISA 763 produce a Th1 like immune response and protect against L. amazonensis infection. Using serums of vaccinated mice, immunoproteomic assay was made in order to identify and select the immunodominant antigens, and therefore develop third generation vaccines.Fil: Germano, Maria Jose. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaXXXVI Scientific Meeting of the Cuyo Biology SocietyMendozaArgentinaSociedad de Biología de CuyoTech Science Press2020info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/conferenceObjectReuniónJournalhttp://purl.org/coar/resource_type/c_5794info:ar-repo/semantics/documentoDeConferenciaapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/204449Immune response to develop a vaccine against leishmaniasis; XXXVI Scientific Meeting of the Cuyo Biology Society; Mendoza; Argentina; 2018; 4-40327-9545CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.techscience.com/biocell/v43nSuppl.4Nacionalinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T10:01:21Zoai:ri.conicet.gov.ar:11336/204449instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 10:01:22.696CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Immune response to develop a vaccine against leishmaniasis
title Immune response to develop a vaccine against leishmaniasis
spellingShingle Immune response to develop a vaccine against leishmaniasis
Germano, Maria Jose
Leishmania
Vaccine
Immunology
title_short Immune response to develop a vaccine against leishmaniasis
title_full Immune response to develop a vaccine against leishmaniasis
title_fullStr Immune response to develop a vaccine against leishmaniasis
title_full_unstemmed Immune response to develop a vaccine against leishmaniasis
title_sort Immune response to develop a vaccine against leishmaniasis
dc.creator.none.fl_str_mv Germano, Maria Jose
author Germano, Maria Jose
author_facet Germano, Maria Jose
author_role author
dc.subject.none.fl_str_mv Leishmania
Vaccine
Immunology
topic Leishmania
Vaccine
Immunology
purl_subject.fl_str_mv https://purl.org/becyt/ford/1.6
https://purl.org/becyt/ford/1
dc.description.none.fl_txt_mv Leishmaniasis is an infectious disease caused by flagellated parasites belonging to Leishmania genus and transmitted by phlebotominae sandflies. Leishmaniasis is distributed in 98 countries of the world; in Argentina, the endemic areas are the Northwest and Northeast regions of the country.Leishmania parasites present two different stages: the intracellular amastigote localized in the mammalian polymorphonuclear cells and the extracellular promastigote, presents in the sanfly vector. This disease manifests different clinical forms: cutaneous, mucocutaneous or visceral leishmaniasis, mainly depending on the species of Leishmania involved.There is currently no vaccine against human leishmaniasis. In order to develop that, it is important to considerate the immunology of susceptibility and resistance to leishmaniasis, which depends on the genetic background of host and the specie, and even the specie of Leishmania involved. In consequence, it is possible that a vaccine is effective against one Leishmania specie but not against others.Our research group has been developing first generation vaccine, using Total L. amazonensis Antigens (TLA) which combined with Poly(I:C) and/or Montanide ISA 763 produce a Th1 like immune response and protect against L. amazonensis infection. Using serums of vaccinated mice, immunoproteomic assay was made in order to identify and select the immunodominant antigens, and therefore develop third generation vaccines.
Fil: Germano, Maria Jose. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina
XXXVI Scientific Meeting of the Cuyo Biology Society
Mendoza
Argentina
Sociedad de Biología de Cuyo
description Leishmaniasis is an infectious disease caused by flagellated parasites belonging to Leishmania genus and transmitted by phlebotominae sandflies. Leishmaniasis is distributed in 98 countries of the world; in Argentina, the endemic areas are the Northwest and Northeast regions of the country.Leishmania parasites present two different stages: the intracellular amastigote localized in the mammalian polymorphonuclear cells and the extracellular promastigote, presents in the sanfly vector. This disease manifests different clinical forms: cutaneous, mucocutaneous or visceral leishmaniasis, mainly depending on the species of Leishmania involved.There is currently no vaccine against human leishmaniasis. In order to develop that, it is important to considerate the immunology of susceptibility and resistance to leishmaniasis, which depends on the genetic background of host and the specie, and even the specie of Leishmania involved. In consequence, it is possible that a vaccine is effective against one Leishmania specie but not against others.Our research group has been developing first generation vaccine, using Total L. amazonensis Antigens (TLA) which combined with Poly(I:C) and/or Montanide ISA 763 produce a Th1 like immune response and protect against L. amazonensis infection. Using serums of vaccinated mice, immunoproteomic assay was made in order to identify and select the immunodominant antigens, and therefore develop third generation vaccines.
publishDate 2020
dc.date.none.fl_str_mv 2020
dc.type.none.fl_str_mv info:eu-repo/semantics/publishedVersion
info:eu-repo/semantics/conferenceObject
Reunión
Journal
http://purl.org/coar/resource_type/c_5794
info:ar-repo/semantics/documentoDeConferencia
status_str publishedVersion
format conferenceObject
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/204449
Immune response to develop a vaccine against leishmaniasis; XXXVI Scientific Meeting of the Cuyo Biology Society; Mendoza; Argentina; 2018; 4-4
0327-9545
CONICET Digital
CONICET
url http://hdl.handle.net/11336/204449
identifier_str_mv Immune response to develop a vaccine against leishmaniasis; XXXVI Scientific Meeting of the Cuyo Biology Society; Mendoza; Argentina; 2018; 4-4
0327-9545
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.techscience.com/biocell/v43nSuppl.4
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.coverage.none.fl_str_mv Nacional
dc.publisher.none.fl_str_mv Tech Science Press
publisher.none.fl_str_mv Tech Science Press
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269692122628096
score 13.13397

Publicaciones similares